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The mutable nature of cancer has made it one of the toughest diseases to successfully fight against. 
Due to the aggressive nature of cancer, toxic drugs are administered to stop or slow down the 
growth of cancerous cells. However, most of the conventional treatment methods lack site 
targeting and specificity, therefore, affecting any rapidly dividing cells. Destruction of normal cells 
therefore leads to malfunctioning of body organs. A proposed solution is to use localized drug 
delivery, with nanocomposite-based scaffolds with tuneable biodegradation, biocompatibility, and 
porous structures. These drug- and nanoparticle-based scaffolds were fabricated through solvent 
casting method. Scaffolds containing magnetite nanoparticles were loaded with an experimental 
drug (Dichapetalin M), Tamoxifen (a control cancer drug) for comparison. Morphological study 
of the scaffolds was characterised with a scanning electron microscope. Drug release experiments 
and mechanisms of drug release (kinetics and order of drug release) were studied with ultraviolet 
visible spectrometer. Porosity of the samples were examined with ImageJ software. The inclusion 
of nanoparticles in the scaffold structure increased the pore size and pore diameter which also leads 
to the lowering the yield strength of the scaffold, while pore density and pore area enhanced drug 
diffusion from the scaffold matrix. Implications of the results were discussed for possible 
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1.1 Background and Introduction 
World cancer incidence has been projected to increase by 50 % (from 14 million to 21 million) 
from the year 2012 to 2030 [1]. It was also reported that, global cancer deaths are projected to 
increase by 60 % (from 8 million to 13 million) by 2030 [1].  
In a human body, cells naturally multiply and die on regular bases [2]. This self-destruction of 
cells when noting their deficiency or old age is termed as apoptosis [3,4]. This regular and normal 
division of cells is scientifically termed as mitosis [2]. Sometimes, genes undergo an abnormal 
change or mutation [5]. Since the genes are part of the cell’s ‘brain’ (nucleus), an abnormal change 
to the genes could possibly lead to an abnormal rate at which cells divide [5]. In most cases, these 
defective cells divide more rapidly and die less frequently as compared to the normal cells [5,6,7]. 
This rapid division of cells causes the establishment of a lump, commonly known as a tumour 
[5,6,7]. For the tumour to survive, it forms blood vessels that acts as an avenue for oxygen and 
nutrients, for its survival and growth [6]. This phenomenon is known as metastasis, describing the 
invasive nature of cells, especially cancerous cells [8] (Fig. 1.1).   
What makes cancer lethal is when these tumours begin to interfere with the vital body organs [6]. 
Among the commonly interfered vital organs are the lungs, the breasts, the brain, the stomach, and 
more [7]. Early detection is key to positive outcomes. However, treatment almost becomes 






Figure 1.1: Metastasis, and the Invasive Nature of Cancerous Cells. 
 
1.2 Problem Identification 
Currently, the conventional cancer treatment methods include surgery, bulk systemic 
chemotherapy, and targeted therapy [8]. Surgery is the removal of cancerous cells or tumour 
through incision, laser, or low temperature cases [8]. However, surgery does not guarantee the 
removal of residual cancerous cells. Hence, the remaining cancerous cells later develops into 
tumours that may require post treatment surgeries [6,8]. Due to the aggressive nature of cancer, 
toxic drugs are administered during chemotherapy to stop or slow down the growth of cancerous 
cells [8]. However, chemotherapy is generally non-targeted and therefore affects any rapidly 
dividing cells, such as hair cells [8]. Destruction of normal cells therefore leads to malfunctioning 
of body organs [9]. 
Targeted therapy is a treatment method that seeks to target the nature by which cancerous cells 
divide and spread. Targeted therapy therefore uses small-molecule drugs to counterattack 
cancerous cells [8]. However, cancerous cells soon develop resistance to targeted medicine in this 





Most of the conventional treatment methods lack site targeting and specificity. Localized drug 
delivery has been highly studied in recent times for cancer treatment [9,10]. Thus, localized drug 
delivery could target the tissue sites specifically, while avoiding the exposure of non-target 
tissues/cells to toxic drugs. The current work is aimed at employing a nanoparticle-based 3D 
scaffold with desirable mechanical degradation, and drug release mechanisms for targeted cancer 
treatment [9,10,14]. This approach would ensure that scaffolds subsequently degrades by the 
natural metabolic activities. 
 
1.3 Motivation and Justification 
 
The birth of tissue engineering has somewhat been a beneficial substitute to tissue grafting and 
alloplastic tissue repair due to challenges like bio-incompatibility and donor unavailability [11, 
14]. Tissue engineering has made it possible for the use of highly porous biodegradable scaffold 
biomaterials as dependable avenues for the regeneration of tissues [11,12].  
Biological scaffolds are biologically engineered, temporary, artificial extracellular matrices 
essential for the regeneration of 3D functional tissues for medical purpose [25,26]. The common 
polymer used in making medical scaffolds is polylactic acid (PLA) which degrades in the human 
body releasing lactic acid (harmlessly released to the body) [26]. However, recent studies have 
displayed the possibility of combining PLA with polyethylene glycol (PEG), or PLA with poly-
glycolic acid (PGA), making the composite structures more hydrophilic and biocompatible [26]. 
These structures (scaffolds) ought to possess several characteristics depending on their 
functionalities. These characteristics involve ‘appropriate’ biocompatibility, biodegradability, 





scaffolds do not only serve as avenue for tissue regeneration, but also as avenues for drugs release 
to vigorously counterattack any abnormality such as cancer [9,10,14].  
Studies have shown that under proper constructive mechanisms (such as solvent casting), 3D 
scaffold can be an avenue for cell seeding that can lead to tissue regeneration [13]. The novelty of 
this project lies in the possibility of combining laser ablation and localized drug delivery with 
nanocomposite-based scaffolds with tuneable biodegradation, biocompatibility, and porous 
structures to mitigate potential side effects associated with the current conventional cancer 
treatment [9,10].  
1.4 Objectives and Expected Outcome 
The expected outcome of this project is to develop a nanoparticle-based solvent cast 3D scaffolds 
with significant pore structures as well as mechanical capability to enhance localized heating and 
controlled cancer drug release.  
This outcome will be validated through series of objectives: 
❖ Highly porous 3D nanoparticle-based scaffolds will be fabricated with poly-lactide-acid-
co-poly-ethylene-glycol (PLA-PEG) through solvent casting techniques. 
❖ Optical characterization of the 3D Scaffolds using scanning electron microscope (SEM). 
❖ The porosity of the scaffolds would be well characterized: pore sizes, pore densities and 
pore distribution would be analysed with ImageJ software.  
❖ Drug encapsulated scaffolds will be studied for the kinetics of the cancer drug release.  
❖ SolidWorks would be used to mechanically simulate the static conditions of the scaffold in 







2.0 Literature Review 
2.1 Statistics on Cancer 
According to the World Health Organisation (WHO), cancer is the second leading cause of deaths 
in the world, causing over 9.6 million deaths in 2018 (out of every 6 deaths, 1 is caused by cancer) 
[1]. The leading cause of deaths globally is cardiovascular diseases [39]. In 2018, lung cancer was 
recorded to have the highest mortality rate among other cancer types, followed by colorectal, 
stomach, liver and breast cancer [1,5,39]. The type of cancer with the highest incidence rate is lung 
cancer alongside breast cancer, followed by colorectal, prostate, stomach, and liver cancer [39]. 
Studies have shown that cancer is mainly caused by the following: high body mass index, low 
fruits and vegetables intake, lack of physical action or exercise and excessive use of tobacco and 
alcohol [5].  
The WHO further points out that 70 % of the cancer-caused deaths occurred in the middle- and 
low-income countries, where the key cause of this huge number is the late-stage presentation and 
inaccessibility of diagnosis and treatments [5]. It was reported that there were over 90 % of 
treatment services available in high-income countries and less than 30 % available treatment 
services in the low-income countries [1]. 
 
2.2 Possible Cancer Interventions 
Cancer interventions or treatment methods are categorized into three objectives: Primary 
treatment, Adjuvant treatment and Palliative treatment [17]. A cancer treatment method is 
prescribed based on the overall health of the patient, type of cancer or the stage in which the cancer 





The aim of primary treatment is to remove the tumour from patient’s body or aggressively kill the 
cancerous cells [17]. Any cancer treatment can be used for this objective depending on the 
responsiveness or nature of the cancer being dealt with [17]. However, a common primary 
treatment is oncological surgery [17]. Oncological surgery removes the cancer or much of the 
cancer [8,17]. Oncological surgery is applied in the case of a tumour causing tremendous pain or 
pressure [17]. Despite this intervention, oncological surgery is limited to solid tumours situated at 
one place thus treatment against spread-out cancer will be impossible to be eliminated with this 
method alone [8,17]. Other treatment methods are then incorporated [17].   
The aim of adjuvant treatment is to kill any leftover cancer cells after the primary treatment is 
done. Adjuvant treatment is a supplement to the primary objective of cancer treatments [17]. A 
common adjuvant treatment is chemotherapy [18]. Chemotherapy involves the administering of 
aggressively toxic drugs into the patient’s body for the aim of preventing cancerous cells division, 
elimination of cancerous cells ‘food’ generators (enzymes and hormones) or directly killing 
cancerous cells [18].  
Radiotherapy is another adjuvant treatment method [17,19]. This cancer treatment method 
involves the use of high energy particles such as X-Rays, electron beams, gamma rays to attack 
cancerous cells deposited in a specific region in the body [19]. Radiotherapy does affect nearby 
healthy cells but not effective as chemotherapy does [19]. In most cases, normal cells recover from 
radiation effect and go back to their ordinary tasks [19]. Radiation attacks cancerous cells by 
initiating small breaks in their DNA which cause them to seize growth and mitosis hence death of 
the cells occurs [19].  
Palliative cancer treatments aim at relieving side effects during cancer treatments [17]. These 





of a palliative cancer treatment is hyperthermia [20]. By incorporating hyperthermia to 
radioactivity, cancer treatment specificity will improve. Hence, healthy tissues will not be as 
affected as compared to radioactivity functioning on its own [20]. Apart from its palliative role, 
hyperthermia can take up a primary role. Hyperthermia involves subjecting the tumour to 
temperature of about 43oC to 45oC which kills tumour cells or make them more responsive to 
radiotherapy [21]. Example of these tumours are breast cancer tumours and melanoma tumours 
mostly found on the surface of the body [21]. Hyperthermia also assists in the easy diffusion of 
chemotherapy drugs [21].  
 
2.3 Unresolved Issues 
This section involves a discussion on some of the side effects and issues presented by the 
conventional cancer treatments methods. 
 
2.3.1 Lack of Site Targeting and Specificity 
 
One unresolved issue with the available cancer treatment methods is the impossibility of scoping 
out the impact unleashed onto the body by these treatment methods [8]. Most cancer treatment 
methods are invasive and do not only target cancerous cells but also nearby healthy cells [8,9]. 
There is a lack of site targeting and specificity in the conventional treatments available [8]. Bulk 
systemic chemotherapy tends to expose the entire body to toxic drugs [18]. In other words, it 
involves the administering of toxic drugs that aggressively attack rapidly dividing cells including 
but not limited to cancerous cells [18]. This means any rapidly dividing cells will be exposed to 
the gruesome effect of these drugs [8,18]. Cells that often encounter these drugs include white 





decrease of white blood cells, the body has less potential to fight infections that regularly attack it. 
Apart from the loss of the general degree of the body immunity, chemotherapy can cause the loss 
of hair. This hair loss occurs in the head, breast areas for women, eye lashes, eye lids, pubic areas, 
arm pits, including the legs depending on the harshness of the type of chemotherapy drug used 
[22, 24]. Hair follicles are part of the rapidly dividing body cells which means toxic chemo drugs 
attack them as well [22, 24].  
 
2.3.2 Recurrence of cancer 
Recurrence of cancer refers to the revival of cancer in a local, nearby, or distant region of the body 
[23]. This occurs due to the breaking away of a tumour and its reestablishment in another area 
[23]. It can also be caused by the failure of oncological surgery to perfectly remove the cancerous 
cells from the region in which the tumour was removed [8,17,23]. It can also be caused by the 
dormant nature of some types of cancer [23]. But after an activity trigger, the cancer begins to 
vigorously divide [23].  
Among the factors that would lead to a high recurrence probability of a cancer type include larger 
tumour size, lack of radiation after removal of cancerous cell, and cancerous cells that easily 
mutate making them resistant to adjuvant treatment [23]. The use of multiple cancer treatment 
methods has been employed to respond to the recurrent nature of cancer [23].  
 
2.4 Engineered Scaffolds and Tissue Regeneration 
With the inevitable recurrence of diseases, injuries, and trauma, it has become immensely 
necessary to invest expertise in the field of tissue repair, replacement, or regeneration [27]. An old 





from one site to the diseased or injured site within the same body [11,27]. An allograph is a transfer 
of tissue from one body to another injured or diseased body. Despite the significant aid that these 
treatment methods have offered, limitations are inescapable.  Autographs are profoundly painful, 
expensive, and susceptible to donor-site morbidity [11,14,27]. Allographs are challenged by the 
scarcity of enough tissues to serve the needs of the numerous tissue-replacement-demanding 
patients. Aside that challenge, there is a fear of tissue rejection by the immune system of the patient 
as well as a possibility of introducing infections or diseases into the receiving body [14,27].  
A rapidly growing field of study is tissue regeneration [11,12]. Tissue regeneration is a supported  
renewal and growth of a tissue on the diseased or injured site. This regeneration is made possible 
through combining health body cells with a highly porous scaffold biomaterial [11,12]. Under 
conducive biochemical and physio-chemical factors, this highly porous scaffold biomaterial will 
guide the growth of new tissue [11,12,13] (Fig. 2.1). Regardless of the type of tissue to be 
regenerated, when designing the highly porous scaffold biomaterial several requirements must be 
considered: biocompatibility, biodegradability, mechanical properties, scaffold architecture and 
manufacturing technology [25,26].  
 





2.5 Biopolymers for scaffold design 
 
Biopolymers are polymers originating from living organisms. Like all polymers, monomers 
covalently bond onto one another forming a chain-like structure called a polymer [28]. Among the 
well-known polymers include polylactic-co-glycolic (PLGA), poly(ε-caprolactone), polylactic 
acid (PLA), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), chitosan and more. [28] (Table 2.1).  
Aside their abundancy and unique biological characteristics, biopolymers are also biocompatible 
[29]. This means they can effectively work in contact or in close vicinity to the body and bodily 
fluids without altering the normal functions or triggering any side effect or allergic reactions. It is 
their biocompatibility factor that has provided basis for intense use in the biomedical field (Table 
2.2). Biopolymers are used in tissue scaffolding, artificial grafting, controlled drug delivery, as a 
bone filler material, and implantation [30].  
Table 2.1: Classification of well-known biopolymers. 
Biodegradable Nonbiodegradable 
Bio-Based Fossil-Based Bio-Based 
Plants Microorganisms Animals  







e.g. PEA, PPF, 
PTT, etc. 
PE (LDPE, 
HDPE), PP, PVC 
Lignin PHF Chitosan 
(polysaccharides) 
PGA PET, PPT 









Casein (protein) PVOH PC 
PLA (from starch or 
sugar cane) 
 Leather (protein)  Epoxy 
PE Polyethylene, LDPE Low density polyethylene, HDPE High density polyethylene, PP Polypropylene, 
PVC Polyvinyl chloride, PHA Polyhydroxyalkanoates, PHF Poly-1-hydroxymethylethylene 
hydroxymethyl-formal, PEA Poly(ethylene adipate), PPF Poly(Propylene Fumarate), PTT 





alcohol), PET Polyethylene terephthalate, PPT Polypropylene Terephthalate, PU Polyurethane, PC 
Polycarbonates.  
 
Table 2.2: Common polymers and their medical significance. 





▪ PLA degrades within the body 
after incision has healed. 
▪ Copolymers of PLA and PGA 
are more useful than 
homopolymers of PLA and PGA 
because their rate of degradation 
can be adjusted.  
▪ Devices made of PLA-
PGA copolymer have been 
used for the controlled 
release of antibiotics, 
anticancer and antimalarial 
agents, contraceptives, 
hormones, insulin, narcotic 




▪ Insoluble in water 
▪ Biodegradable 
▪ Suture (stitches holding 
together the edges of a 
wound or surgical incision)  
▪ Drug delivery 





▪ Tailored biodegradation rate 
(depending on the molecular 
weight and copolymer ratio) 
▪ Potential to modify surface 
properties to provide better 
interaction with biological 
material 
▪ Degrades rapidly than PGA and 
PLA 
▪ Ligament/Tendon repair 
▪ Biodegradable Stents 
▪ Bone fixation devices 
 
2.6 Nanoparticles-based Scaffolds 
Nanoparticles are particles with dimensions measured in nanometres (nm; 1 nm = 10-9 m). 
Nanoparticles can naturally be found in the world and also can be produced through everyday 
human activities. Due to their uniquely small size, nanoparticles can have unique material 





Nanomedicine, a branch of nanotechnology, has recently been highly beneficial especially in the 
tissue regeneration field. Nanoparticles run from being used as drug delivery vessels in porous 
biodegradable scaffolds, to being used as an enhancive entity in targeted cancer treatment 
(Photothermal therapy) [32]. According to Sahai et al., “Nanomedicines are used to 
bind/encapsulate in porous biodegradable scaffolds in the form of antibiotics, proteins, growth 
factors, specific micro- and macro-nutrients to promote tissue regeneration.” [33]. 
It has been scientifically proven that when cancerous cells are subjected to temperature ranging 
from 43oC to 45oC, the cells undergo programmed cell death [34]. Nanoparticles are essential in 
raising up the cellular temperatures to that range hence performing targeted cancer treatment [34].  
 
2.7 Laser Ablation and Localized Cancer Treatment 
Laser ablation is generally a process of focusing an energetic laser beam onto an area for the goal 
of removing or killing materials in the irradiated region [35]. It is also referred to photoablation 
[36]. It involved the use of heat produced from light rays’ concentration to remove undesired 
material from the irradiated region [36].  
According to Schena et al (2017), laser ablation is done using a laser beam which transports the 
laser light into the tissue at a specific wavelength. The wavelength defines the properties of the 
laser and the interaction with biological tissue [37]. Laser ablation could be involved in localized 
treatment of cancer [37]. It eradicates cancer tumours without removing them [38]. Laser ablation 
subjects a tumour with appropriate temperature that will initiate cancerous cells’ death [34,38].  





2.8 Scope of Project 
The first chapter presented the background studies on the subject area. The problem statement, 
motivation, goal, and objectives as well as expected outcomes were clearly highlighted in chapter 
one.  
Extensive literature survey was presented in the second chapter of this report. Statistics on cancer 
incidence and mortality rates were presented. Moreover, the current conventional methods of 
cancer treatment were present with their challenges for future directions. Review on biopolymers 
and nanocomposite scaffolds were also presented for the design of tissue engineered scaffolds to 
serve as alternative treatment modalities for cancer treatment.  
Moreover, the third chapter presents the design, materials, and methods. The design covers the 
requirements and materials selection. Methodologies comprised of experimental procedures, 
computational simulation and different materials characterization and techniques. Examples of test 
cases include, but not limited to, determining the effect of porogen on the porosity of PLA-PEG, 
effect of nanoparticles on PLA-PEG, effect of drugs release on PLA-PEG scaffold. Also, 
mechanical characterization include tensile and compressive strength.  
The fourth chapter presents a section on the analysis, results, and scientific discussions. 
Implications of the results are then discussed for the development of potential cancer treatment 
with nanocomposite scaffolds. 
The fifth chapter presents the concluding remarks, recommendations, limitation, and suggestions 








3.0 Materials and Methods 
3.1 Design Requirements 
The design requirements are summarized in Table 3.1. 
Table 3.1: Table showing design requirements and indicative remarks. 
Design requirement Meaning 
Biocompatibility Device should be able to support cellular activities as an 
attempt to regenerate a new tissue, without bringing harm to 
the host tissue. 
Biochemical Degradation Device should be able to indicate mass loss as a sign of 
biodegradation over time. 
Porosity Device should support the presence and appropriate 
distribution of pores essential for cell seeding and tissue 
regeneration.  
Geometry Device should be able to cover the entire affected area that 
will encounter laser ablation and guide the tissue regeneration. 
Mechanical performance Device should have sufficient potential to withstand the 
dynamic mechanical reality of the human body.  
Drug release mechanism  Device should be able to periodically(controllably) release 
drugs that would kill any residual cancerous cells 







3.2 List of Materials 
Cancer drugs: Tamoxifen (control drug), Dichapetalin M (Dic M) (experimental drug) were 
supplied by the Biochemistry and Chemistry Department, The University of Ghana. Magnetite, 
gold nanoparticles and polyvinylpyrrolidone (PVP) were supplied by Dr. Danyuo Yiporo at Ashesi 
University, poly-ethylene glycol (PEG) was procured at a chemical shop in Accra, while poly-
lactic-acid (PLA) filament was supplied by the mechanical lab at Ashesi University. Porogen (salt), 
distilled water, ethanol, acetone, di-chloro-methane, falcon tubes (15 ml and 50 ml), and other 
consumables were procured from a chemical shop in Accra. Lastly, surface-treated tissue culture 
plate (6/12-wells plates) were procured from Life Science Plasticware (Illinois, USA). 
 
3.3 Experimental Design and Procedures 
3.3.1 Solvent casting 
Solvent casting process involves the solidification of poly-lactic-acid-co-poly-ethylene-glycol 
polymer through the escape of a highly volatile organic solvent from the mixture. PLA filament 
was cut into pellets (1 cm rods) and weighted according to experimental design (Table 3.2) using 
an Analytical balance (Mettler Toledo®, ME 103, Columbus, Ohio, USA). An organic solvent, 
dichloromethane (DCM) was used to melt the polymers (PLA and PEG) at 90℃ − 100℃ in an 
airtight glass container (to prevent DCM from escaping). Physical process with stirring was done 
at regular interval to ensure a homogenous polymer solution were obtained. The polymer solutions 
were left at room temperature for 24 h to enable all particles within the solution to dissolve. Control 
scaffold comprised of PLA, cast in circular mini glass petri dishes (diameter = 30 mm), while the 
porogen (95% of polymer mass) was sprinkled onto the cast polymer immediately. The density of 





However, PVP was then added to the magnetite nanoparticles (Fe3O4) and dissolved with DCM. 
The PVP- Fe3O4 solution was then introduced to designed sample codes C-E (Table 3.2). About 
95 % of grinded salt particulates were introduced to sample codes A-E as porogen to enhance the 
porosity of the scaffolds. A volume of 4 mL of cancer drugs were introduced into sample codes A, 
B, C and E to study the effect of Tamoxifen and Dic. M on the microstructure of the scaffolds. 
Drug loaded scaffolds were subsequently used for drug release kinetics and for the study of cell 
viability in the future. Samples were then cast and allowed to dry in an open (at room temperature). 
The volatility of the DCM enhances its evaporation from the scaffold after casting. The illustration 
in Figure 3.1 showed the solvent casting process. Leaching was then carried out after 24 h of 
casting. Samples were saturated with 500 ml of distilled water inside glass beakers. Fresh distilled 
water was replaced at 12 hr interval for about 5 days to ensure the salt (porogen) has dissolved and 
leached out. Experimental scaffolds were placed on filtered papers and dried at laboratory 
temperature. Scaffolds at this stage were then ready for drug release experiments, optical 
characterization, and mechanical testing. 
Table 3.2: Table showing sample cases and measurements needed. 
Sample 
Code 
PLA PEG Fe3O4 nano-
powder 
Cancer Drugs (4 
mL) 
Grinded Table 
Salt (NaCl as 
porogen) 




5% of Polymer 
Mass (0.750 g) 
Tamoxifen Dic M 
 
95% of polymer 
mass (14.250g) 
Control  100 15.0       
Sample A 80 12.0 20 3.0  ✓   ✓  
Sample B 80 12.0 20 3.0   ✓  ✓  
Sample C 80 12.0 20 3.0 ✓  ✓   ✓  





Sample E 80 12.0 20 3.0 ✓   ✓  ✓  
 
✓ The presence of that entity in the respective sample code: Tamoxifen Control Drug, Dic M 
Dichapetalin M (Experimental Drug), PLA Poly-lactic-acid, PEG Poly-Ethylene-Glycol.  
 
 
Figure 3.1:  An image-flow portraying solvent casting and particulate leaching processes. 
 
3.3.2 Kinetics of the Cancer Drug Release  
The study of cancer drug release would require biological fluids. In view of this, phosphate buffer 
saline (PBS) solution was prepared at pH 7.4 to simulation physiological conditions. Initial 
absorbance of the prepared drug solution was obtained using an ultraviolet visible 
spectrophotometer (Jenway Genova Bio Spectrophotometer, 720601, Jenway, Cole-Parmer Ltd 
Stone Staffordshire, ST15 0SA, United Kingdom). Drug release was done in triplicates. Sections 





Ject-III single use syringes. Drug release was done at 37 ℃ inside an orbital incubator shaker set 
at 60 rpm (Incu-shaker Mini, H1001-M, 2600 Main Street Extensions, NJ, USA). Absorbances 
were recorded at peak value at specific wavelengths for both drugs and converted to concentration 
of drug release as a function of time. Samples after the UV-vis measurements were stored in a 
ULab 1.5 ml microcentrifuge tube in a deep freezer for future use. Drug release was guided by 
Beer-Lambert Law: 
Beer Lambert Law is mathematically expressed over the visible range of light absorption in the 
sample at known wavelengths given by:  
𝑨(𝛌) = 𝐞(𝛌) 𝒍 𝒄          (3.1) 
where A(λ) is the Absorbance, e(λ) is the molar absorptivity constant which changes dependent on 
wavelength (250-400 nm), l is the path length (cross-section of cuvette through which light travel 
through the liquid), and c is the concentration of solution. Figures 3.2a and 3.2b are the pictures of 
the Jenway Genova Bio Spectrophotometer and Incu-shaker Mini, respectively. 
 





3.3.3 Investigating the order of drug release 
Investigation on the order of drug release was performed by making use of rate laws and graphical 
models. The order of drug release is basically a study of how the rate of drug release is affected by 
the progressive fall in concentration of the drug. The orders of drug release were investigated 
through the following equation (3.2): 
𝑹 = 𝒌[𝑪]𝒏                                                                                                                               (3.2) 
where R is the rate of concentration fall, k is the rate constant, C is the concentration and n is the 
order of release. For zero order n = 0, for first order n = 1 and for second order n = 2.  
 
To test whether a set of experimental data abides to the first order of release, a graph of the natural 
log of concentration against time was plotted. If the resultant graph is a negative slope straight 
line, then the set of experimental data is that of first order. To test whether a set of experimental 
data abides to the second order of release, the first order test is performed, which will result into a 
curve. After that test, a graph of the inverse of concentration against time is plotted. If the resultant 
graph is a positive slope straight line, then the graph is a second order graph. The kinetics models 
including zero order, first order, second order and Huguchi were used to examine the rate of drug 
release from the polymeric matrices. The linear relations of the model equations are summarized 









Table 3.3: Linear Relations of the Model Equations [40]. 
Model Equation 
Zero-order 𝐶𝑡 = 𝐶𝑜 + 𝑘𝑜𝑡 








𝐶𝑡 = 𝐶𝑜 + 𝑘𝑜𝑡
1
2 
where ko is the rate constant for the given model, Ct is the concentration at time t, and Co is the 
initial concentration.   
Higuchi model was discovered in 1961 by a legendary professor Takeru Higuchi [43]. This model 
basically explained the order or mechanism of drugs transportation in polymeric matrices. To test 
whether a drug abides to this model, concentration would be plotted against the square root of 
time. The resulting graph must be a positive slope straight line.  
Q = kot1/2                                                                                                                                            (3.3) 
where Q is the cancer drug concentration, ko is the Higuchi constant, and t
1/2 is the square root of 
the time in hours.  
To test the linearity of the resultant test graphs, the coefficient of determination (R2) was used. The 
coefficient of determination is a statistical tool, ranging from 0-1 that allows us to measure the 
goodness of fit. The closer a graph’s R2 value is to 1, the better the graph’s fit to a certain model.  
Concentration versus time graphs of all samples would be passed through the three tests, then 
coefficients of determination (R2) of each resultant model test graphs would be compared and the 
resultant test graph with the highest R2 would inform us that a particular concentration versus time 





3.3.4 Optical Characterisation  
Morphological characteristics of the microstructures of the scaffolds were investigated with 
Phenom scanning electron microscope (Phenom, Eindhoven, The Netherlands). Imaging was done 
at different resolutions. Porosity of the samples were subsequently done using ImageJ software 
(Wayne Rasband, University of Wisconsin-Madison, USA). Following the study of porosity, the 
samples were characterised to determine the pore sizes, pore densities and pore distribution. 
 
3.3.5 Mechanical analysis with SOLIDWORKS 
Figure 3.3 presents CAD models of PLA scaffold, PLA-PEG scaffold, and PLA-PEG-
Nanoparticles scaffold (260.47 µm by 286.32 µm by 20 µm). The necessity to come up with these 
designs was for the goal of knowing how pore density and pore sizes affects the mechanical 
strength of the scaffold through the application of tension force.  
The force applied was a product of the design yield strength and the perpendicular area of the 
surface where the force would be applied. The design yield strength was calculated from dividing 
the actual PLA yield strength with a safety factor of 3.5. The yield strength was 20 MPa, the tensile 
force applied on the scaffold was 0.00157 N and the compressive force was 0.44958 N. Tensile 
loading was done by applying force in opposite directions, while compressive forces were applied 
on the surface of the scaffolds (while the opposite face was statically fixed.   
After obtaining the force values needed, a mesh was created (Fig. 3.4) for every CAD sample, and 






Figure 3.3: CAD model of a piece of: (a) PLA scaffold, (b) PLA-PEG scaffold, and (c) PLA-PEG-
Nanoparticles scaffold. 
 








4.0 Results, Analysis and Discussion 
4.1 Morphological Analysis of the 3D Scaffolds 
Figure 4.1 below is a collection of images displaying the resultant scaffolds after solvent casting 
and particulate leaching. One clear difference is the colour of samples that contain nanoparticles, 
from ones that did not contain nanoparticles. Scaffolds containing magnetite nanoparticles were 
darker due to the black colour of Iron (II,III) oxide, powder. Samples with porous with the presence 
of salt (as the porogen) and porosity was associated with rough surfaces especially when 
nanoparticles were incorporated.  
 
Figure 4.1: From top left (to the right): Control (CL), Sample A, Sample B. From bottom Left (to 
the right): Sample C, Sample D, Sample E. 
CL A B 





Figure 4.2-I displays the microscopic images of three scaffolds. From the three images, it was 
observed that the scaffold sample with just PLA (Control sample) did not lack porosity (Fig. 4.2-
Ia), despite the fact that no porogen was added. The presence of the micropores/macropores is 
because of the volatility of DCM which also act as a pore forming agent especially when it 
evaporates from the polymer matrix during solidification. A mean pore diameter of 4.897 µm per 
50 pores were measured within the PLA sample. PEG is a hydrophilic polymer and its presence in 
PLA (PLA-co-PEG sample) (Fig. 4.2-Ib) helps to enhance the porosity of the scaffolds and the 
porosity becomes more pronounce when porogen such as salt particulates were introduced and 
leached out during casting. That is, PEG is a hydrophilic polymer which enhance the pore density 
of the scaffold. Also, leaching out the salt which acts as a porogen enhances the pore density of 
the scaffold which could enhance drug diffusion, cell seeding, and protein absorption. Thus, the 
water-soluble porogen (table salt) dissolved in the distilled water hence leaving a pit-like pore 
structure essential for proliferation/percolation of cells, air, or nutrients. However, the size of pores 
varies.  
The effect of Iron (II,III) oxide powder (nanoparticles) played a vital role in increasing the pore 
sizes/pore area (Fig. 4.2-Ic). A mean pore diameter of 18.845 µm per 50 pores was reported for a 
scaffold that contained nanoparticles (Fig. 4.2-IIc). This result is almost twice the pore diameter 
of 8.823 µm per 50 pores that was measured for a PLA-PEG scaffold that lacks iron nanoparticles 








(a)      (b)        (c) 
 
 
Figure 4.2-I: Scanning Electron Microscopy Images: (a) Morphology of PLA scaffold, (b) 
Morphology of PLA-PEG scaffold, (c) Morphology of PLA-PEG-Nanoparticles scaffold. 
 
 
The pore sizes for the control sample ranges from 3-7 𝜇𝑚 with dominance of 4.1-5.0 𝜇𝑚 
(representing 32%) (Fig. 4.2IIa). Pore size/pore area were found to increase from 3-17.4 𝜇𝑚 for 
PLA-PEG sample containing a pore forming agents (Fig. 4.2IIb). Dominated pores for this sample 
was within the range of 7-10.12 𝜇𝑚 (representing 42%) (Fig. 4.2IIb). Larger pore areas with less 
pore density were observed when PLA-PEG samples were loaded with magnetite nanoparticles 


















4.2 Kinetics of Cancer drug release 
Figure 4.3 displays the relationship of absorbance against wavelength for the control drug 
(Tamoxifen drug) (Fig. 4.3a) and experimental drug (Dic M) (Fig. 4.3b). Figure 4.3a shows that 
the maximum absorbance for the Tamoxifen is 1.081 at a wavelength of 297 nm, while Dic M had 
a peak absorbance of 0.581 at a wavelength of 295 nm.  
Standard curves, which depict the relationship between concentration and absorbance are 
presented (Fig. 4.4). Both graphs reveal a common trend of increase in concentration as absorbance 
increases. However, the release concentration and absorbance of Tamoxifen were higher than the 
Dic M (Fig. 4.4). The standard curves would help researchers working with tamoxifen and Dic M 
to easily interpolate with measured absorbance to determine a given concentration of drugs release.   
 






 Figure 4.4: Standard curves: (a) Tamoxifen and (b) Dic M. 
 
In terms of kinetics, the data (Fig. 4.5) shows an exponential fall in drug concentration with time. 
Drug release was higher within the first day but decreased exponentially with time. However, there 
was a transient decrease and sudden increase in drug release. Due to the mutable nature of 
cancerous cells, medical researchers have come into an awareness of coming up with cancer drugs 
that contain a sense of unpredictability. Thus, before the cancer cells gets accustomed to a certain 
manner of drug behaviour, a sudden change in the drug behaviour could occurs to keep up with 
the mutable cancer. This is good for treating and suppressing recurring diseases such as cancer 









Figure 4.5: Concentration Versus duration of drug release: (a)Tamoxifen-containing samples (b) 
Dic. M-containing samples. 
 
4.3 Order of drug release 
For a graph that predicts the response variable (drug release) to acceptably exhibit a certain model 
of drug release, its R2 value must be in the range 0.95 to 1[42].  
From Table 4.1 and Table 4.2, we observe that both Tamoxifen and Dic M cancer drugs have low 





the abundance of more data, the graph might fully show a leaning towards Higuchi model of drug 
release (a model that is widely used in polymeric matrix systems) [43]. 
Table 4.1: Comparison of R2 values for Tamoxifen-containing samples.  
 R2  VALUES 
1st order model test 2nd order model test Higuchi model test 
Sample A: PLA-
PEG(80:20)-Tamoxifen 




0.3434 0.1421 0.5991 
R2 value average 0.3784 0.2104 0.5882 
 
Table 4.2: Comparison of R2 values for Tamoxifen-containing samples. 
 R2  Values 
1st order model test 2nd order model test Higuchi model test 
Sample B: PLA-
PEG(80:20)-Dic M 




0.2529 0.0623 0.6005 
R2 value average 0.2519 0.0737 0.5992 
 
As a reminder, zero order of release means that the rate of drug release is not affected by the 
progressive fall in the concentration. In other words, the rate of the fall in concentration (drug 
release from the scaffold) is time in dependent [44] (Figure 4.6a). First order of release means that 





scaffold [45]. In the first order of release, the rate of decrease in molar concentration depends on 
one reactant alone. The second order is a release in which the rate of drug release is dependent on 
the concentration of two reactants or the concentration of one reactant to the second power. 
 
Figure 4.6: Order of Drug Release and Drug Release Mechanism: (a) Zero Order, (b) First Order, 
(c) Second Order or Higuchi 
 
4.4 Mechanical analysis with SolidWorks 
From the mechanical simulation of the three scaffold CAD models, displacements (deformation), 
stress and strain are shown in Figures 4.7 and 4.8. When tension and compressive forces are 
applied, the least displacement was experienced by the PLA sample, whereas the highest 





increase in pore density and diameter plays a significant role in the strength of the scaffold. This 
also means the modulus or perhaps the hardness of the scaffold will be reduced with pore density 
and the presence of PEG and nanoparticles in the scaffolds since deformation was more 
pronounced in axial loading. This in a way will ensure that, the properties of the scaffolds are 
lowered to match with the mechanical properties of normal tissues. Generally, compressive 
strength was higher than the tensile results. Compressive strength closes microcracks/microvoids, 
which tensile test opens this pre-existing cracks/voids. Hence, the structure will resist more loads 
in compression than in tension as shown in Tables 4.3 and 4.4.  
 
 
 Figure 4.7: Displacement simulation images of: (a) PLA scaffold (b) PLA-PEG scaffold (c) PLA-






Figure 4.8: Displacement simulation images of: (a) PLA scaffold (b) PLA-PEG scaffold (c) PLA-
PEG-Nanoparticles scaffolds during compressive test. 
 
Table 4.3: Table displaying maximum displacement, stress and strain during tension test. 






PLA 0.04043 0.8065 0.0004623 
PLA-PEG 0.07141 1.928 0.001484 
PLA-PEG-Nanoparticles 0.16610 1.537 0.001225 
 
Table 4.4: Table displaying maximum displacement, stress and strain during compression test. 







PLA 0.5407 53.81 0.03315 
PLA-PEG 1.580 143.0 0.07951 







5.0 Conclusions and Future Works 
5.1 Remarks and Recommendation 
The pursuit for cancer drugs for site targeting and specificity has yielded to several useful remarks. 
One, is the understanding that apart from the conventional methods of scaffold fabrication, which 
may be efficient but significantly expensive, one can embark in the fabrication through solvent 
casting process. The biopolymers used can ensure that tuneable characteristics such as 
biodegradation, biocompatibility, porosity, and hydrophilicity are controlled to fit a precise 
biological task.  
The mutable nature of cancerous cells had led to a perpetual demand for new cancer drugs that 
would be locally and controllably administered. As part of this project, an experimental drug , 
Dichapetalin M, was analysed against an industrially available drug, Tamoxifen. This 
experimental drug exhibited desirable preliminary characteristics such as transient drug release 
and the Higuchi model of release which generally agree with the controllability requirement for 
locally delivered drugs.  
Mechanical analysis of the samples informed us that the inclusion of PEG not only promotes 
hydrophilicity into the sample, but also plays part in the increase of pores sizes and pores density. 
PEG and Fe3O4 nano powder plays a crucial role in increasing the overall pore diameter at 
physiological conditions (37℃, pH 7.4, and 60 rpm). Drug release was enhanced by natural 
diffusion through the porous matrices of the scaffolds. Hydrolysis also plays a major role in drug 
diffusion, especially when the polymer gets soaked in phosphate buffer saline solution. 
The significance of mechanical and structural changes in the scaffold enhances the goal of attaining 






Throughout the project several limitations managed to squeeze their way into resisting the 
expected progress rate or the expected outcome. 
The manual grinding of porogen and cutting of PLA into pellets proved to be exceedingly time 
consuming. Both activities took a duration of one week to accomplish them. Had there been a 
machine, in the proximity of my reachability, that would have grinded the table salt into fine 
particulates, that would have been appreciated. 
The process of liquifying PLA pellets proved to be quite time consuming. I am hopeful, there could 
be more efficient method of liquefying PLA pellets soon.  
Inclusion of the porogen (grinded table salt) into the polymeric liquid proved to be another 
limitation to an expected outcome. The sprinkling of porogen into and onto the pouring polymeric 
liquid was somewhat uncontrolled. The uneven sprinkling of the porogen led to uneven 
distribution of pores in the sample. Thus, the uneven distribution cause uneven pores creation 
which might affect the transportation of localized drugs, nutrients, and oxygen to adjacent body 
tissues.  
Aside the practical limitations, the outbreak of Coronavirus disease-19 undeniably did affect the 
project progress pace as well as changing the direction onto which the project was initially 
intended. However, this experience has taken us into a place of knowing that it is possible to work 






5.3 Future works 
Dynamic effects of nanoparticles on laser heating and drug release is an area that should be 
investigated. This will provide insights on how nanoparticles-based porous scaffold structures 
could enhance localized temperature to induce apoptosis in cancerous cells. The drug loaded 
scaffolds containing nanoparticles can provide a synergy to both hyperthermia and localized drug 
delivery.  
Investigation on the biochemical degradation of the scaffolds via mass loss is another area that can 
be worked on. This would be done through determining the degradation rates, mechanism of 
degradation, and structural integrity of the scaffold (mechanical properties). 
A series of mechanical tests such as hardness, stiffness, tensile and compression strength, can also 
be manually done at regular interval during degradation and the results received would be 
translated into a software of choice for the goal of mechanically simulating the static conditions of 
the scaffold in terms of stress distribution, deformation and elastic strains. 
Cell seeding and biocompatibility tests can also be carefully carried out on the scaffolds which 
could be followed by cell viability (determination of dead and living cells in a sample) studies via 
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Materials and Equipment Used 
Materials and Equipment Description 
 
LARK 
Ethanol AR (2.5L), 99.9%, MW=46g/mol 






DAEJUNG CHEMICALS &METALS CO. LTD 
Gyeonngi-do, Korea 
 
Distilled water (25L) 
FINAP ENTERPRISE  








Sodium Chloride (500g, MW= 101.96g/mol) 
BDH Laboratory Supplies 







Buffer solution Ph 10 at 250C (500mL) 













Hydrochloric Acid (1 mol/L) 
SCS Schulchemieservice GmbH 
At Burgweiher 3  
























Mettler Toledo® (ME 103) 
Analytical balance 
Mettler-Toledo International, Inc 
Columbus, Ohio, USA 
 
AG ADVANGENE  
12well, surface-treated tissue culture plate 
Life Science Plasticware 
















Single use syringe (5mL) 
Changzhou Huichun Medical Equipment Co. 
LTD 
Changzhou, Jiangsu, China 
 
ULAB  




Poly-lactide-acid (PLA) pellets 
 
SDFCL 
Poly-Ethylene-Glycol (PEG) 500g 
S D FINE-CHEM LTD 









New Jersey, USA 
 
ALDRICH 
Iron (II,III) oxide, nanopowder 
SIGMA-ALDRICH Inc 
St. Louis, MO 63103, USA 
 





























Absorbance against Duration data 
SAMPLE A    
DAY A1 A2 A3 A 
0 1.081 1.081 1.081 1.081 
1 0.132 0.239 0.276 0.216 
2 0.133 0.131 0.171 0.145 
3 0.165 0.072 0.057 0.098 
4 0.063 0.082 0.067 0.071 
5 0.048 0.050 0.007 0.035 
6 0.035 0.074 0.074 0.061 
7 0.256 0.070 0.090 0.139 
8 0.108 0.066 0.079 0.084 
9 0.097 0.198 0.064 0.120 
10 0.033 0.026 0.046 0.035 






SAMPLE B    
DAY B1 B2 B3 B 
0 0.581 0.581 0.581 0.581 
1 0.329 0.266 0.296 0.297 
2 0.111 0.095 0.161 0.122 
3 0.000 0.031 0.268 0.100 
4 0.094 0.066 0.102 0.087 
5 0.041 0.056 0.018 0.038 
6 0.188 0.057 0.077 0.107 
7 0.167 0.135 0.121 0.141 
8 0.117 0.089 0.077 0.094 
9 0.152 0.205 0.089 0.149 
10 0.080 0.033 0.080 0.064 




SAMPLE C    
DAY C1 C2 C3 C 
0 1.081 1.081 1.081 1.081 
1 0.267 0.304 0.264 0.278 
2 0.230 0.176 0.193 0.200 
3 0.026 0.023 0.069 0.039 
4 0.108 0.126 0.161 0.132 
5 0.108 0.035 0.099 0.081 
6 0.077 0.083 0.086 0.082 
7 0.120 0.197 0.115 0.144 
8 0.098 0.051 0.087 0.079 
9 0.124 0.101 0.145 0.123 
10 0.038 0.025 0.063 0.042 
11 0.113 0.127 0.107 0.116 
     
     
SAMPLE E    
DAY E1 E2 E3 E 





1 0.031 0.312 0.290 0.211 
2 0.172 0.179 0.212 0.188 
3 0.094 0.013 0.051 0.053 
4 0.139 0.140 0.176 0.152 
5 0.034 0.070 0.037 0.047 
6 0.134 0.123 0.168 0.142 
7 0.153 0.139 0.106 0.133 
8 0.086 0.158 0.115 0.120 
9 0.105 0.120 0.100 0.108 
10 0.091 0.092 0.103 0.095 
11 0.109 0.162 0.013 0.095 
 
 
 
 
 
